GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8<sup>+</sup>/CD4<sup>+</sup> T cells and TILs in patients with locally advanced or metastatic solid tumours.

Br J Cancer · 2025 · PMC12356974 · PMID 40490502

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Consistent with previous studies, the ratio of CD4 + and CD8 + T cells to regulatory T cells on day 21 after GX-I7 administration compared to baseline showed an increasing trend, and the increase was statistically significant in the 240–480 and 1200–1700 ug/kg groups (Fig. 3f ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8&lt;sup&gt;+&lt;/sup&gt;/CD4&lt;sup&gt;+&lt;/sup&gt; T cells and TILs in patients with locally advanced or metastatic solid tumours.

The sentences

GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8<sup>+</sup>/CD4<sup>+</sup> T cells and TILs in patients with locally advanced or metastatic solid tumours.